Phase II trial of sunitinib (Sutent, SU11248) maintenance therapy after induction platinum-based chemotherapy [cisplatin, carboplatin, etoposide, irinotecan] in patients with extensive-stage small cell lung cancer.

Trial Profile

Phase II trial of sunitinib (Sutent, SU11248) maintenance therapy after induction platinum-based chemotherapy [cisplatin, carboplatin, etoposide, irinotecan] in patients with extensive-stage small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2014

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2010 Planned end date changed from 1 Jun 2011 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top